Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer - LUMINANCE

Study identifier:D419QC00007

ClinicalTrials.gov identifier:NCT04774380

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer (LUMINANCE)

Medical condition

Extensive-stage Small Cell Lung Cancer

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

152

Study type

Interventional

Age

-

Date

Study Start Date: 11 Nov 2021
Primary Completion Date: 12 Jun 2023
Study Completion Date: 02 Jan 2025

Study design

Allocation: Non-Randomized
Endpoint Classification: -
Intervention Model: Single Group
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria